Receptor tyrosine kinase expression in astrocytic lesions: similar features in gliosis and glioma.
The purpose of this study was to determine if the expression of receptor tyrosine kinases would distinguish astrocytosis from astrocytoma. Because the expression of this family of receptor proteins is greater in higher-grade tumors, a graded series of both reactive and neoplastic astrocytic lesions in humans was evaluated. The reactive processes included both mild gliosis and severe (intense) gliosis. The two immunocytochemically detected membrane receptor proteins, p145 and p185, are those encoded by the kit and neu genes, respectively. Semi-quantitative assessments were made independently for the frequency and intensity of astrocytic immunostaining together with corollary immunocytochemical staining to detect glial fibrillary acidic protein. It was found that both mild gliosis and low-grade astrocytomas only minimally express these receptors. In contrast, severe gliosis and high-grade neoplasms consistently express these receptors at much higher levels. In both astrocytosis and astrocytomas, a cell with abundant perikaryal cytoplasm is most likely to be immunoreactive, often with dense reaction product concentrated at the periphery of the somal cytoplasm. The extent and pattern of immunoreactivity in high-grade astrocytomas preclude the interpretation that all immunoreactive cells were merely reactive astrocytes. We conclude that the expression of these receptors per se does not differentiate astrocytic neoplasia from reactive astrocytosis. Second, we conclude that immunocytochemically detectable levels of neu or kit receptor expression is not constitutive in normal astrocytes and in some stages of astrocytic neoplasia. On the basis of these findings, we speculate that some neoplastic astrocytes maintain and manifest the capacity to respond to transitory exogenous stimuli, as do reactive astrocytes. This reaction could include the elaboration of receptor tyrosine kinases. Alternatively, even if the function of these receptors in gliosis differs from that in gliomas, the common expression could still reflect an "active" state shared by astrocytes in these two processes.
Kristt
D A
DA
Department of Pathology, University of Maryland School of Medicine, Baltimore.
Reedy
E
E
Yarden
Y
Y
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001253:Astrocytes / Q000201:enzymology* / Q000473:pathology; D001254:Astrocytoma / Q000201:enzymology* / Q000473:pathology; D001932:Brain Neoplasms / Q000201:enzymology* / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D004705:Endocytosis; D004790:Enzyme Induction; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D005909:Glioblastoma / Q000201:enzymology* / Q000473:pathology; D005911:Gliosis / Q000201:enzymology* / Q000473:pathology; D006801:Humans; D007124:Immunoenzyme Techniques; D007223:Infant; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000096:biosynthesis* / Q000235:genetics; D011505:Protein-Tyrosine Kinases / Q000096:biosynthesis* / Q000235:genetics; D011518:Proto-Oncogene Proteins / Q000096:biosynthesis* / Q000235:genetics; D019009:Proto-Oncogene Proteins c-kit; D018719:Erb-b2 Receptor Tyrosine Kinases; D011956:Receptors, Cell Surface / Q000096:biosynthesis* / Q000235:genetics; D016184:Receptors, Colony-Stimulating Factor / Q000096:biosynthesis / Q000235:genetics
D009363:Neoplasm Proteins; D011505:Protein-Tyrosine Kinases; D011518:Proto-Oncogene Proteins; D019009:Proto-Oncogene Proteins c-kit; D018719:Erb-b2 Receptor Tyrosine Kinases; D011956:Receptors, Cell Surface; D016184:Receptors, Colony-Stimulating Factor